This website is intended for UK Healthcare professionals only. Other UK residents please visit astrazeneca.co.uk

A New Era in MIBC Care

NOW APPROVED in the UK: The IMFINZI NIAGARA regimen* – the FIRST and ONLY perioperative IO regimen approved in the UK for your cisplatin-eligible, resectable MIBC patients^1,2

Indication: IMFINZI in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as monotherapy adjuvant treatment after radical cystectomy, is indicated for the treatment of adults with resectable MIBC²

Give your eligible patients with MIBC the potential for improved outcomes vs NAC by offering IMFINZI from the start¹

Start with neoadjuvant IMFINZI + gem-cis, then continue with adjuvant IMFINZI monotherapy following RC:¹

Schematic outlining dosing in the neoadjuvant phase. Schematic outlining dosing in the adjuvant phase.

†Patients with a body weight of 30 kg or less must receive weight-based dosing of Imfinzi at 20 mg/kg.²

PD-L1 testing is not required to start treatment with IMFINZI¹

MIBC patients with a body weight of ≤30 kg must receive weight-based dosing of IMFINZI at 20 mg/kg²
Administer IMFINZI prior to chemotherapy on the same day²
Refer to the SmPC of appropriate chemotherapeutic agent for dosing alongside IMFINZI²
IMFINZI is administered as a 60-minute IV infusion after dilution²

Patients with borderline renal function (CrCl ≥40 mL/min/1.73 m2 to <60 mL/min/1.73 m2) received split-dose cisplatin 35 mg/m² on days 1 and 8 of each neoadjuvant cycle in the NIAGARA trial^1,2

A holistic uro-oncology care team approach is essential to unlocking the full potential of the perioperative IMFINZI NIAGARA regimen* for eligible patients with MIBC in the UK

For more information, explore our resource hub or contact
an AstraZeneca representative

View resources

*The perioperative IMFINZI NIAGARA regimen is defined as neoadjuvant IMFINZI + gem-cis followed by adjuvant IMFINZI as a single agent after RC^1,2

MIBC, muscle-invasive bladder cancer; gem-cis, gemcitabine-cisplatin; RC, radical cystectomy; Q4W, once every 4 weeks; Q3W, once every 3 weeks; SmPC, summary of product characteristics; IV, intravenous; CrCl, creatinine clearance; IO, immune-oncology; PD-L1, programmed death-ligand 1.

Powles T, et al. N Engl J Med. 2024;391(19):1773-1786 (including Supplementary Appendix and Protocol).
IMFINZI, Summary of Product Characteristics.

GB-67157 | September 2025

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling ‌‌‌0‌‌‌8‌‌‌‌‌0‌‌‌‌0‌‌‌ ‌‌7‌‌‌‌‌‌8‌‌‌3‌‌‌ ‌‌0‌‌‌‌‌0‌‌‌‌3‌‌‌‌3‌‌‌.

This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.

Cookie Policy

A New Era in MIBC Care

Give your eligible patients with MIBC the potential for improved outcomes vs NAC by offering IMFINZI from the start1

A holistic uro-oncology care team approach is essential to unlocking the full potential of the perioperative IMFINZI NIAGARA regimen* for eligible patients with MIBC in the UK

For more information, explore our resource hub or contactan AstraZeneca representative

Abbreviations and References

Give your eligible patients with MIBC the potential for improved outcomes vs NAC by offering IMFINZI from the start¹

For more information, explore our resource hub or contact
an AstraZeneca representative